论文部分内容阅读
目的:研究巨噬细胞移动抑制因子(macrophage migralion inhibitory factor,MIF)-173位点单核苷酸多态性与影响前列腺癌预后因素的关系。方法:应用聚合酶链反应限制性片段长度多态性(PCR-RFLP)分析259例前列腺癌患者MIF基因-173位点的多态性,比较不同基因型与前列腺癌患者的前列腺癌特异性抗原(PSA)、Gleason评分、临床分期的关系、结果:MIF-173 *C等位基因与PSA、Gleason评分、临床分期具有显著相关性(adjusted OR=4.39,10.73,15.68;95%CI:2.43～7.93,5.36～21.50,7.40～33.23)。结论:MIF-173*C等位基因可能与前列腺癌的预后有关,携带MIF-173*C等位基因的前列腺癌患者可能预后较差。
Objective: To investigate the relationship between single nucleotide polymorphism (MIF) -173 of macrophage migraion inhibitory factor (MIF) and prognosis of prostate cancer. Methods: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to analyze the polymorphism of MIF gene -173 locus in 259 cases of prostate cancer patients. Prostate cancer-specific antigen was compared between different genotypes and prostate cancer patients (PSA), Gleason score and clinical stage. Results: MIF-173 * C allele had significant correlation with PSA, Gleason score and clinical stage (adjusted OR = 4.39,10.73,15.68; 95% CI: 7.93, 5.36 ~ 21.50, 7.40 ~ 33.23). Conclusions: The MIF-173 * C allele may be associated with the prognosis of prostate cancer, and patients with prostate cancer carrying the MIF-173 * C allele may have a poor prognosis.